Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) shares traded down 1.8% during trading on Tuesday . The company traded as low as $1.60 and last traded at $1.64. 39,199 shares traded hands during trading, a decline of 91% from the average session volume of 424,500 shares. The stock had previously closed at $1.67.
Matinas Biopharma Trading Down 1.8%
The business’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $0.91. The stock has a market cap of $8.34 million, a price-to-earnings ratio of -0.34 and a beta of 1.40.
Matinas Biopharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Read More
- Five stocks we like better than Matinas Biopharma
- Most active stocks: Dollar volume vs share volume
- Is Qualcomm Tesla’s Next Rival in Autonomous Driving?
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The Quiet Before the Catalyst: Vertical Aerospace’s Next Move
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
